“On Thursday, the FDA released its updated 2024 Language Access Plan, taking another key step toward addressing language barriers that impact health equity and strengthening language access to health information and services for the public, including people with Limited English Proficiency and people with disabilities. The plan also supports FDA efforts to identify interpretation language assistance, translate, and make important documents accessible, as well as digital and web content into multiple languages. The Language Access Program, led by the FDA’s Office of Minority Health and Health Equity, is a part of the FDA’s ongoing work to help individuals make informed decisions about their health.”

Learn More

FDA’s 2024 plan provides practical guidance and action steps for the Agency and its programs to ensure greater access to its information and services.

Suggested For You

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Reflections on the Recent Donanemab Approval

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 8th, 2024

FDA Works to Reduce the Spread of Misinformation

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

regulatory intelligence

June 26th, 2024

New Details on Diversity Action Plans Provided by the US FDA

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology